GOSSAMER BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
GOSSAMER BIO, INC. (GOSS) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $9.62 per share as of 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2022-08-09
- 2022-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $9.62.
- 2022-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $9.27.
- 2021-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $8.41.
- 2021-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $8.15.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value |
|---|---|
| 2022-06-30 | $9.62 10-Q · filed 2022-08-09 |
| 2022-03-31 | $9.27 10-Q · filed 2022-05-10 |
| 2021-09-30 | $8.41 10-Q · filed 2021-11-08 |
| 2021-06-30 | $8.15 10-Q · filed 2021-08-09 |
| 2021-03-31 | $8.08 10-Q · filed 2021-05-06 |
| 2020-09-30 | $5.96 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |